Saturday , October 21 2017
Home / Resources / Articles / Reduced Systolic Blood Pressure Observed with Liraglutide

Reduced Systolic Blood Pressure Observed with Liraglutide

The reduced SBP was also weakly correlated with weight loss….

The study was done to quantify the effect of liraglutide on systolic blood pressure (SBP) and pulse in patients with type 2 diabetes (T2D), and assess the influence of covariates on observed SBP reductions, and was set up as a patient-level pooled analysis of six phase 3, randomized trial.

The results included 2792 randomized patients. In the intention-to-treat population (n=2783), mean [±SE] SBP reductions from baseline with liraglutide 1.2mg (2.7 [0.8] mmHg) and 1.8mg (2.9 [0.7] mmHg) once daily were significantly greater than with placebo (0.5 [0.9] mmHg; P=0.0029 and P=0.0004, respectively) after 26 weeks, and were evident after 2 weeks. Liraglutide was also associated with significantly greater SBP reductions than glimepiride and, at a dose of 1.8mg, insulin glargine and rosiglitazone. SBP reductions with liraglutide weakly correlated with weight loss (Pearson’s correlation coefficient: 0.08-0.12; P≤0.0148). No dependence of these reductions on concomitant antihypertensive medications was detected (P=0.1304). Liraglutide 1.2 and 1.8mg were associated with mean increases in pulse of 3 beats per minute (bpm), versus a 1bpm increase with placebo (P<0.0001 for each dose versus placebo).

From the results it was concluded that, liraglutide reduces SBP in patients with T2D, including those receiving concomitant antihypertensive medication.

Practice Pearls:
  • Liraglutide once daily was associated with significant reductions in systolic blood pressure after 26 weeks compared with placebo, with decreases appearing as early as 2 weeks.
  • Reduced systolic blood pressure observed with liraglutide was weakly correlated with weight loss
  • Use of liraglutide may help lower cardiovascular risk in the setting of T2DM.

Reductions in Systolic Blood Pressure With Liraglutide in Patients With Type 2 Diabetes: Insights From a Patient-Level Pooled Analysis of Six Randomized Clinical Trials. J. Diabetes Complicat. 2014 May 01;28(3)399-405, VA Fonseca, JH Devries, RR Henry, M Donsmark, HF Thomsen, J Plutzky